Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.39 |
| ▸ | EGFR | P00533 | 3/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.33 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.33 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1748944 | 0.92 | CTSV (0.40) | PTGDR2MAPTALDH1A1PCSK9LMNA | |
| SCHEMBL1749526 | 0.91 | EGFR (0.37) | PTGDR2EGFRMAP4K1MAPTKDM4E | |
| SCHEMBL1777928 | 0.88 | MAPT (0.48) | PTGDR2MAPTKDM4EHTTLMNA | |
| SCHEMBL2987041 | 0.87 | PTGDR2 (0.36) | PTGDR2EGFRPKMMAP4K1MAPT | |
| SCHEMBL2991481 | 0.86 | PTGDR2 (0.38) | PTGDR2PKMMAP4K1KDM4EALDH1A1 | |
| SCHEMBL1749011 | 0.85 | EGFR (0.40) | PTGDR2EGFRPKMMAP4K1MAPT | |
| SCHEMBL1748508 | 0.84 | L3MBTL1 (0.44) | PTGDR2EGFRMAPTKDM4EALDH1A1 | |
| SCHEMBL1748729 | 0.84 | MEN1 (0.34) | PTGDR2EGFRMAP4K1MAPTKDM4E | |
| SCHEMBL1748718 | 0.83 | PTGDR2 (0.39) | PTGDR2PKMMAPTKDM4EALDH1A1 | |
| SCHEMBL1778913 | 0.82 | PTGDR2 (0.39) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968566-B2 | Pyrrolo(2,3-b) pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2011-06-28 | — | — | US | disclosed |
| US-20090233956-A1 | NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2009-09-17 | — | — | US | disclosed |
| US-7528147-B2 | Pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2009-05-05 | — | — | US | disclosed |
| US-20070093480-A1 | Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2007-04-26 | — | — | US | disclosed |
| CN-1950083-A | Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors | AVENTIS PHARMA SA (FR) | 2007-04-18 | — | — | CN | disclosed |
| EP-1732546-A2 | NOVEL PYRROLO (2,3-B)PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005095399-A2 | NOVEL PYRROLO (2,3-B)PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233956-A1 | NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS | MAP3K19, MAP4K2, MAP3K1 | PTGDR2 806/4885EGFR 569/4885PKM 282/4885 |
| US-20070093480-A1 | Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors | MAP3K19, MAP4K2, MAP3K1 | PTGDR2 806/4885EGFR 569/4885PKM 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.